home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> biomedical companies   |   search    |   registration     |   modification  

registry of biomedical companies

  July 19, 2019
promoting the transfer of scientific know-how between industry and academia
Registry of biomedical companies:

[1] [3] [4] [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Z] 527 active entries

Biota Holdings Limited

10/585 Blackburn Road
Notting Hill, Victoria , 3168

Phone: 61 3 9915 3700
Fax: 61 3 9915 3702

Stock symbol: BTA
Please notice: This entry hasn't been updated by the submitting company for more than 2 years. It could be possible that this company doesn't longer exists.


Biota is a leading anti-infective drug development company, based in Melbourne, Australia.

Biota's initial success was the discovery of zanamivir, the first-in-class neuraminidase inhibitor for the treatment and prevention of influenza. Zanamivir is licensed to GlaxoSmithKline and marketed as Relenza™. Relenza is used to treat seasonal influenza and is currently being stockpiled by various governments for defence against possible pandemic outbreaks of avian (bird) influenza.

Biota also has key partnerships with:

  • Boehringer Ingelheim: where it has a licence and collaboration agreement to develop and commercialise Biota's novel nucleoside analogues, designed to treat hepatitis C virus (HCV) infections and potentially other diseases.
  • MedImmune Inc: where it has a licence and collaboration agreement to develop Biota's lead compounds aimed at RSV (respiratory syncytial virus).
  • Inverness Medical: Biota developed the influenza diagnostics OIA® FLU and OIA® FLU A/B influenza diagnostics, currently marketed as part of the BioStar® range.
  • Daiichi-Sankyo: for the development of second generation influenza antivirals (called LANI or long-acting inhaled neuraminidase inhibitors).

In 2007, Biota completed a phase I clinical trial of its human rhinovirus (HRV) drug for the prevention and treatment of one of the major causes of the common cold which is also thought to be a major cause of exacerbations in patients with chronic obstructive pulmonary disease and asthma.

The Company's research pipeline also extends beyond respiratory diseases, including early stage research targeting the hepatitis C virus (HCV).

Selected Categories:
Product Company   Service Company
- General
- Research

Last update of this entry: June 16, 2008

home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap

Generated by companies 4.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2019 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.